MD Anderson Cancer Center

Stories

Next-generation KRAS drug extends survival in head-to-head lung cancer trial

Academic lead institution for Krascendo 1

Five years after the first KRAS inhibitor reached the market, a next-generation drug beat the existing ones head-to-head. In the Phase III Krascendo 1 trial, divarasib cut the risk of death by 44% and nearly doubled response rates in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Updated Nov 2